Compare DexCom, Inc. (DXCM) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Manhattan Associates Inc — how do they compare? DexCom, Inc. trades at $89.89 (market cap $33.79B), while Manhattan Associates Inc trades at $191.69 (market cap $11.38B). The key difference: DexCom, Inc. is far larger — about 3× Manhattan Associates Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | MANH | |
|---|---|---|
Market Cap | $33.79B | $11.38B |
Sector | Health | Technology |
52-Week High | $89.53 | $220.19 |
52-Week Low | $54.84 | $120.88 |
Enterprise Value | $33.24B | $11.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
MANH trades at $189.98, down 2.92% on the day, but maintains a bullish technical outlook with strong moving average signals and a golden cross formation. The company reported Q2 2026 EPS of $1.39, beating estimates, with cloud revenue growth driving performance. However, high valuation ratios like a P/E of 55.93 and P/B of 72.26 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by Rosen Law Firm, adding a layer of scrutiny.
The stock's upside is supported by analyst consensus with a $210.33 price target and 80% buy ratings, but risks include elevated valuations, potential legal overhangs, and projected net cash flow turning negative in 2026. Investors should weigh robust profitability metrics against these headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
